PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company’s drug candidate, PN6047, effectively reduces neuropathic pain in animal models and the findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported. Furthermore, PN6047 exhibited none of the adverse events typically associated with the conventional opioids like oxycodone and morphine, such as respiratory depression, constipation, itching, or signs of abuse potential. This validates the unique preclinical profile of PN6047, which shows that it acts extremely selectively on the delta opioid receptor distinguishing it fundamentally from conventional opioids that target the mu opioid receptor. PN6047 is Phase II ready!
View Top Employees from PharmNovoWebsite | https://www.pharmnovo.com/ |
Revenue | $5 million |
Employees | 10 (3 on RocketReach) |
Founded | 2008 |
Address | 1 Scheeletorget, Lund, Skane SE-223 81, SE |
Technologies |
JavaScript,
HTML,
Twitter
+9 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Drug Discovery, Healthcare, Biotechnology |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular PharmNovo employee's phone or email?
The PharmNovo annual revenue was $5 million in 2024.
David Kendall is the Chief Scientific Officer of PharmNovo.
3 people are employed at PharmNovo.
PharmNovo is based in Lund, Skane.
The NAICS codes for PharmNovo are [3254, 32541, 32, 325].
The SIC codes for PharmNovo are [28, 283].